Charles River Laboratories ROE 2006-2018 | CRL

Current and historical return on equity (ROE) values for Charles River Laboratories (CRL) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Charles River Laboratories ROE for the three months ending September 30, 2018 was 25.08%.
Charles River Laboratories ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-09-30 $0.14B $1.26B 11.83%
2018-06-30 $0.13B $1.19B 11.73%
2018-03-31 $0.13B $1.14B 12.34%
2017-12-31 $0.12B $1.05B 12.56%
2017-09-30 $0.20B $1.03B 21.35%
2017-06-30 $0.18B $0.97B 20.69%
2017-03-31 $0.17B $0.88B 19.26%
2016-12-31 $0.16B $0.84B 18.61%
2016-09-30 $0.14B $0.87B 17.58%
2016-06-30 $0.14B $0.84B 18.39%
2016-03-31 $0.16B $0.78B 21.11%
2015-12-31 $0.15B $0.74B 21.27%
2015-09-30 $0.15B $0.71B 21.02%
2015-06-30 $0.14B $0.71B 20.56%
2015-03-31 $0.13B $0.67B 18.72%
2014-12-31 $0.13B $0.68B 18.50%
2014-09-30 $0.12B $0.67B 17.53%
2014-06-30 $0.12B $0.68B 17.48%
2014-03-31 $0.11B $0.70B 16.43%
2013-12-31 $0.10B $0.64B 15.94%
2013-09-30 $0.10B $0.66B 16.04%
2013-06-30 $0.09B $0.65B 14.97%
2013-03-31 $0.10B $0.63B 16.01%
2012-12-31 $0.10B $0.60B 16.53%
2012-09-30 $0.11B $0.60B 18.69%
2012-06-30 $0.10B $0.57B 18.65%
2012-03-31 $0.10B $0.56B 18.79%
2011-12-31 $0.11B $0.53B 19.61%
2011-09-30 $-0.26B $0.54B -43.94%
2011-06-30 $-0.31B $0.59B -42.47%
2011-03-31 $-0.32B $0.56B -35.17%
2010-12-31 $-0.34B $0.69B -30.01%
2010-09-30 $0.02B $1.04B 1.85%
2010-06-30 $0.09B $1.39B 6.25%
2010-03-31 $0.11B $1.38B 7.87%
2009-12-31 $0.11B $1.37B 8.73%
2009-09-30 $-0.57B $1.35B -44.54%
2009-06-30 $-0.56B $1.28B -39.30%
2009-03-31 $-0.54B $1.22B -34.25%
2008-12-31 $-0.53B $1.24B -29.81%
2008-09-30 $0.17B $1.95B 8.93%
2008-06-30 $0.17B $1.95B 8.99%
2008-03-31 $0.16B $1.91B 8.66%
2007-12-31 $0.15B $1.86B 8.59%
2007-09-30 $0.15B $1.80B 9.04%
2007-06-30 $0.09B $1.73B 5.70%
2007-03-31 $0.08B $1.64B 5.04%
2006-12-31 $-0.06B $1.60B -3.43%
2006-09-30 $-0.04B $1.55B -2.43%
2006-06-30 $0.01B $1.64B 0.46%
2006-03-31 $0.01B $1.74B 0.79%
2005-12-31 $0.14B $1.83B 8.28%
Sector Industry Market Cap Revenue
Medical Medical Services $6.012B $1.858B
Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Their dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. At Charles River, they are passionate about their role in improving the quality of people's lives. Their mission, their excellent science and strong sense of purpose guide in all that they do, and they approach each day with the knowledge that their work helps to improve the health and well-being of many across the globe. Charles River Laboratories International, Inc. service areas are Basic research, discovery, safety and efficacy, clinical support and manufacturing.
Stock Name Country Market Cap PE Ratio
Express Scripts Holding (ESRX) United States $54.638B 11.29
ICON (ICLR) Ireland $6.920B 21.69
PRA Health Sciences (PRAH) United States $6.277B 25.63
Premier (PINC) United States $5.275B 17.90
INC Research Holdings (SYNH) United States $4.800B 19.38
HealthEquity (HQY) United States $4.740B 99.21
Teladoc (TDOC) United States $3.711B 0.00
AMN Healthcare Services Inc (AMN) United States $2.883B 19.78
NovoCure (NVCR) Jersey $2.674B 0.00
BioTelemetry (BEAT) United States $2.016B 35.61
Medpace Holdings (MEDP) United States $1.851B 22.91
Healthways (TVTY) United States $1.480B 18.20
Intrexon (XON) United States $1.304B 0.00
IKang Healthcare (KANG) China $1.169B 58.03
CareDx (CDNA) United States $1.020B 0.00
Natera (NTRA) United States $0.957B 0.00
China Cord Blood (CO) China $0.802B 21.29
Apollo Medical Holdings (AMEH) United States $0.635B 0.00
Surgery Partners (SGRY) United States $0.618B 0.00
Establishment Labs Holdings (ESTA) $0.521B 0.00
Civitas Solutions (CIVI) United States $0.516B 10.18
OncoCyte (OCX) United States $0.069B 0.00
Interpace Diagnostics (IDXG) United States $0.032B 0.00
Cancer Genetics (CGIX) United States $0.013B 0.00
OpGen (OPGN) United States $0.007B 0.00
FORM Holdings (XSPA) United States $0.005B 0.00
Biocept (BIOC) United States $0.004B 0.00